172739-04-7

Basic information

• Product Name: CIS-2-BENZYLOCTAHYDROPYRROLO[3,4-C]PYRROLE
• Synonyms: CIS-2-BENZYLOCTAHYDROPYRROLO[3,4-C]PYRROLE;(3aR,6aS)-2-benzyloctahydropyrrolo[3,4-c]pyrrole;cis-2-Benzylhexahydropyrrolo[3,4-c]pyrrole
• CAS NO: 172739-04-7
• Molecular Formula: C₁₃H₁₈N₂
• Molecular Weight: 202.3
• Product Categories: pharmacetical
• Mol File: 172739-04-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 299.587 °C at 760 mmHg
• Flash Point: 124.023 °C
• Appearance: /
• Density: 1.074 g/cm³
• Vapor Pressure: 0.00118mmHg at 25°C
• Refractive Index: 1.57
• PKA: 10.83±0.20(Predicted)
• CAS DataBase Reference: CIS-2-BENZYLOCTAHYDROPYRROLO[3,4-C]PYRROLE(CAS DataBase Reference)
• NIST Chemistry Reference: CIS-2-BENZYLOCTAHYDROPYRROLO[3,4-C]PYRROLE(172739-04-7)
• EPA Substance Registry System: CIS-2-BENZYLOCTAHYDROPYRROLO[3,4-C]PYRROLE(172739-04-7)

Safety Data

• Hazardous Substances Data: 172739-04-7(Hazardous Substances Data)

Usage

General Description

CIS-2-BENZYLOCTAHYDROPYRROLO[3,4-C]PYRROLE is a chemical compound with a unique and complex molecular structure. It belongs to the class of organic compounds known as piperidines, which are heterocyclic compounds containing a saturated six-membered ring that contains a nitrogen atom. This specific compound contains a benzyl group attached to the second carbon in the piperidine ring, giving it unique chemical properties. It is commonly used in medicinal chemistry and drug discovery as a building block for the synthesis of biologically active molecules. Its structural features make it a versatile and important intermediate in the development of pharmaceuticals and other organic compounds.

InChI:InChI=1/C13H18N2/c1-2-4-11(5-3-1)8-15-9-12-6-14-7-13(12)10-15/h1-5,12-14H,6-10H2/t12-,13+

Upstream product

• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 1631-26-1 1-benzyl-1H-pyrrole-2,5-dione 
• 189348-38-7 2,5-dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione 
• 165893-99-2 2,5-dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione 
• 370879-53-1 (3aR,6aS)-5-benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione 

Downstream Products

• 1220514-61-3 (4,6-dimethylpyrimidin-5-yl)(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methanone benzylmalonic acid salt 
• 872001-56-4 [(S)-3-[5-(4,6-Dimethylpyrimidine-5-carbonyl)hexahydropyrrolo[3,4-c]pyrrol-2-yl]-1-(3-fluorophenyl)propyl]carbamic acid tert-butyl ester 
• 872001-57-5 {5-[(S)-3-Amino-3-(3-fluorophenyl)-propyl]hexahydropyrrolo[3,4-c]pyrrol-2-yl}-(4,6-dimethylpyrimidin-5-yl)methanone 
• 1220514-59-9 {5-[(S)-3-Amino-3-(3-fluorophenyl)-propyl]hexahydropyrrolo[3,4-c]pyrrol-2-yl}-(4,6-dimethylpyrimidin-5-yl)methanone tartaric acid salt 
• 1220514-67-9 C₂₇H₃₄FN₅O₃ 
• 1220514-58-8 C₂₇H₃₄FN₅O₃*ClH 
• 250275-15-1 tert-butyl (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 

Relevant articles and documents

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS

Compounds of formula (I) that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Practical asymmetric synthesis of RO5114436, a CCR5 receptor antagonist

A practical asymmetric synthesis of a 3,7-diazabicyclo[3.3.0]octane derivative (1), a representative of a new class of potent CCR5 receptor antagonists, is described. The benzylamine stereogenic center of 1 was introduced by a ruthenium-catalyzed asymmetric reductive amination using (R)-MeOBIPHEP as ligand. Aldehyde 4, prepared by Parikh-Doering oxidation, was used without workup in the reductive amination reaction, which not only simplified the process but also overcame the instability of 4. The 3,7-diazabicyclo[3.3.0]octane core was obtained by a [3 + 2] cycloaddition.

Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof

The present application describes selective ligands of formula (I) for neuronal nicotinic receptors (NNRs), more specifically for the α4β2 NNR subtype, compositions thereof, and methods of using the same, wherein X, R1, X, R2, R3, L1, m, n, p, and q are defined in the specification.